SpencerFane®

Advantage CLE: Defining the Boundaries: Recent Rulings Shaping Drug Scope and IP Strategy

December 15, 2026
12:00 pm CT - 1:00 pm CT

This CLE examines recent judicial and regulatory developments shaping the scope of pharmaceutical patent protection, drug labeling, and regulatory exclusivity. The presentation addresses the U.S. Supreme Court's decision in *Hikma v. Amarin* and its potential implications for pharmaceutical manufacturers. It will also examine the evolving scope of orphan drug exclusivity, including the *Catalyst v. Becerra*, the FDA's response, and any recent legislative developments. Together, these developments highlight the interplay between patent law, FDA regulatory authority, and statutory interpretation, as well as practical considerations for attorneys advising pharmaceutical clients on patent protection, regulatory approval, and market-entry strategies.

See the full Advantage CLE 2026 schedule here.

Continuing Legal Education (CLE) credits are pending in Alabama, Arizona, Arkansas, California, Colorado, Florida, Illinois, Kansas, Louisiana, Minnesota, Missouri, Nebraska, Nevada, New Mexico, New York, Oklahoma, South Carolina, South Dakota, Tennessee, Texas, and Utah. CLE credit application and approval processes vary per state and may not be available after certain state deadlines. Please email education@spencerfane.com if you have questions about credits.